Here are five things to know:
1. The agreement covers Cerapedics’ i-FACTOR Peptide Enhanced Bone Graft. Premier members will have access to i-FACTOR special pricing and pre-negotiated terms.
2. The contract goes into effect Dec. 1, 2016.
3. The i-FACTOR Bone Graft is based on synthetic small peptide (P-15) technology to support bone graft through cell attachment and activation.
4. The technology has premarket approval from the FDA and supported by Level 1 human clinical data.
5. Premier includes 3,750 hospital members in the United States and 130,000 other provider organizations.
“We are pleased to announce our new agreement with Premier because it will help us provide a growing number of surgeons with the advanced biologic they need to stimulate a natural bone healing process in patients with degenerative cervical disc disease,” said Glen Kashuba, CEO of Cerapedics. “We look forward to the continued expansion of i-FACTOR Bone Graft commercialization into the new year.”
More articles on orthopedic devices:
Zimmer Biomet leads hip & knee orthopedic implant market
EOS Imaging to begin operating out of South Korea
17 spine devices receive FDA 510(k) clearance in October
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
